- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT05210634
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy Participants
11. května 2022 aktualizováno: Canopy Growth Corporation
A Two-Phase, Randomized, Double-Blind, PlaceboControlled Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy Participants
This is a two-phase, randomized, double-blind, placebo-controlled, within-participant crossover study to assess the safety, tolerability, PK, and PD of five oral doses of CHI-915 versus placebo in healthy adult participants ages 18-55 years.
Přehled studie
Typ studie
Intervenční
Zápis (Aktuální)
21
Fáze
- Fáze 1
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
Minnesota
-
Saint Paul, Minnesota, Spojené státy, 55114
- Nucleus Network
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
18 let až 55 let (Dospělý)
Přijímá zdravé dobrovolníky
Ano
Pohlaví způsobilá ke studiu
Všechno
Popis
Inclusion Criteria:
- Is a healthy adult aged 18-55 years (inclusive) at the time of screening.
- Has a body mass index between 18 and 30 kg/m2.
- Is judged by the Investigator to be in generally good health at screening based on the results of a medical history, physical examination, 12-lead ECG, and clinical laboratory test results. Laboratory results outside of the reference range deemed to be acceptable will be documented as not clinically significant at the discretion of the Investigator.
- For women of childbearing potential, has a negative serum pregnancy test (β-human chorionic gonadotropin [hCG]) at the Screening Visit and a negative urine pregnancy test at intake to the research facility.
- Must be adequately informed of the nature and risks of the study and give written informed consent prior to screening.
- Is, in the Investigator's opinion, reliable, able, and willing to comply with all protocol requirements and procedures (including scheduled visits).
Exclusion Criteria:
- Women who are pregnant, lactating, breastfeeding, or planning a pregnancy.
- Women of childbearing potential, or men who are sexually active with a woman of childbearing potential, who are unwilling or unable to use an acceptable method of contraception (abstinence or the use of a highly effective method of contraception, including hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom, vasectomy, or intrauterine device) from at least 21 days prior to the first dose of study medication until 28 days after the last dose of study medication. Participants with same sex partners or who maintain abstinence do not require contraception.
- Person has history of diagnosis related to hepatic function and/or significantly impaired hepatic function (alanine aminotransferase [ALT] >3x upper limit of normal [ULN] or total bilirubin [TBL] >2 x ULN) OR the ALT or aspartate aminotransferase (AST) >2 x ULN and TBL >2 x ULN (or international normalized ratio [INR] >1.5).
- Has a history of epilepsy.
- Has used tobacco/nicotine-containing products on more than 10 occasions within 30 days of dosing with study IP or during the study.
- Has used any prescription drugs or herbal supplements (except hormonal contraception) within 30 days prior to receiving the first dose of IP, unless approved by the Investigator and stable for at least 30 days prior to the first dose of IP through the final study visit.
- Use of any over-the-counter drugs, vitamins, or supplements within 24 hours prior to dosing with the IP.
- Has or has previously had a positive result for the presence of Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibodies (HCVAb), or human immunodeficiency virus (HIV) antibodies.
- Has a positive breath, urine, or serum test for ethanol or a positive urine screen for cocaine, THC, barbiturates, amphetamines, methamphetamines, benzodiazepines, methylenedioxymethamphetamine, phencyclidine, methadone, or opiates at the Screening Visit or prior to IP administration.
- Any clinically significant condition or abnormal finding at the Screening Visit that would, in the opinion of the Investigator, preclude study participation or interfere with evaluation of the IP.
- Has a history of a known significant allergic condition, significant drug-related hypersensitivity, or allergic reaction to any compound or chemical class related to cannabis, including phytocannabinoids and cannabinoid analogues, or excipients utilized within the IP.
- Has taken grapefruit products and/or Seville oranges within the 7 days prior to dosing with study medication or during the study.
- Is taking a prohibited medication or supplement including warfarin, clobazam, valproic acid, phenobarbital, mTOR inhibitors, oral tacrolimus, and St. John's Wort within 30 days prior to receiving the first dose of IP or during the study.
- Has used cannabis, synthetic cannabinoid, or cannabinoid analogues (e.g., dronabinol, nabilone), hemp products, synthetic cannabinoid receptor agonists (e.g., spice, K2), or any cannabidiol (CBD) or THC-containing product (e.g., Sativex, Epidiolex) within 4 weeks of the Screening Visit or during the study and has used cannabis on more than 25 occasions in the last 12 months.
- Meets criteria for past-year Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)-defined psychiatric disorder, or moderate to severe substance use disorder.
- Has a lifetime history of psychosis or schizophrenia or a first-degree relative experiencing psychosis or schizophrenia.
- Endorses current suicidal intent as indexed by endorsement of questions #4 or #5 on the Columbia-Suicide Severity Rating Scale (C-SSRS).
- Has suspected or confirmed cardiovascular disease.
- Has participated in any investigational product or device study within 30 days prior to receiving the first dose of IP or is scheduled to participate in another investigational product or device study during the course of this study.
- Demonstrates behavior indicating unreliability or inability to comply with the requirements of the protocol.
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Jiný
- Přidělení: Randomizované
- Intervenční model: Crossover Assignment
- Maskování: Trojnásobný
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Komparátor placeba: Group 1: Placebo
Single oral administration of 4 ml of Placebo MCT oil
|
THCv in MCT oil
|
Aktivní komparátor: Group 2: 12.5 mg THCv (CHI-915)
Single oral administration of 12.5 mg THCv in MCT oil
|
THCv in MCT oil
|
Aktivní komparátor: Group 3: 25 mg THCv (CHI-915)
Single oral administration of 25 mg THCv in MCT oil
|
THCv in MCT oil
|
Aktivní komparátor: Group 4: 50 mg THCv (CHI-915)
Single oral administration of 50 mg THCv in MCT oil
|
THCv in MCT oil
|
Aktivní komparátor: Group 5: 100 mg THCv (CHI-915)
Single oral administration of 100 mg THCv in MCT oil
|
THCv in MCT oil
|
Aktivní komparátor: Group 6: 200 mg THCv (CHI-915)
Single oral administration of 200 mg THCv in MCT oil
|
THCv in MCT oil
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Incidence, type and severity of AEs/SAEs
Časové okno: Day 1
|
Incidence, type and severity of AEs/SAEs
|
Day 1
|
Incidence, type and severity of AEs/SAEs
Časové okno: Day 8
|
Incidence, type and severity of AEs/SAEs
|
Day 8
|
Incidence, type and severity of AEs/SAEs
Časové okno: Day 15
|
Incidence, type and severity of AEs/SAEs
|
Day 15
|
Incidence, type and severity of AEs/SAEs
Časové okno: Day 22
|
Incidence, type and severity of AEs/SAEs
|
Day 22
|
Incidence, type and severity of AEs/SAEs
Časové okno: Day 29
|
Incidence, type and severity of AEs/SAEs
|
Day 29
|
Incidence, type and severity of AEs/SAEs
Časové okno: Day 36
|
Incidence, type and severity of AEs/SAEs
|
Day 36
|
Change in blood pressure
Časové okno: Day 1
|
Change in systolic and diastolic blood pressure measured in mmHg
|
Day 1
|
Change in heart rate
Časové okno: Day 1
|
Change in heart rate measured in beats per minute
|
Day 1
|
Change in respiratory rate
Časové okno: Day 1
|
Change in respiratory rate measured in breaths per minute
|
Day 1
|
Change in body temperature
Časové okno: Day 1
|
Change in body temperature measured in degrees Celsius
|
Day 1
|
Change in blood pressure
Časové okno: Day 8
|
Change in systolic and diastolic blood pressure measured in mmHg
|
Day 8
|
Change in heart rate
Časové okno: Day 8
|
Change in heart rate measured in beats per minute
|
Day 8
|
Change in respiratory rate
Časové okno: Day 8
|
Change in respiratory rate measured in breaths per minute
|
Day 8
|
Change in body temperature
Časové okno: Day 8
|
Change in body temperature measured in degrees Celsius
|
Day 8
|
Change in blood pressure
Časové okno: Day 15
|
Change in systolic and diastolic blood pressure measured in mmHg
|
Day 15
|
Change in respiratory rate
Časové okno: Day 15
|
Change in respiratory rate measured in breaths per minute
|
Day 15
|
Change in heart rate
Časové okno: Day 15
|
Change in heart rate measured in beats per minute
|
Day 15
|
Change in body temperature
Časové okno: Day 15
|
Change in body temperature measured in degrees Celsius
|
Day 15
|
Change in blood pressure
Časové okno: Day 22
|
Change in systolic and diastolic blood pressure measured in mmHg
|
Day 22
|
Change in respiratory rate
Časové okno: Day 22
|
Change in respiratory rate measured in breaths per minute
|
Day 22
|
Change in heart rate
Časové okno: Day 22
|
Change in heart rate measured in beats per minute
|
Day 22
|
Change in body temperature
Časové okno: Day 22
|
Change in body temperature measured in degrees Celsius
|
Day 22
|
Change in blood pressure
Časové okno: Day 29
|
Change in systolic and diastolic blood pressure measured in mmHg
|
Day 29
|
Change in heart rate
Časové okno: Day 29
|
Change in heart rate measured in beats per minute
|
Day 29
|
Change in respiratory rate
Časové okno: Day 29
|
Change in respiratory rate measured in breaths per minute
|
Day 29
|
Change in body temperature
Časové okno: Day 29
|
Change in body temperature measured in degrees Celsius
|
Day 29
|
Change in blood pressure
Časové okno: Day 36
|
Change in systolic and diastolic blood pressure measured in mmHg
|
Day 36
|
Change in heart rate
Časové okno: Day 36
|
Change in heart rate measured in beats per minute
|
Day 36
|
Change in respiratory rate
Časové okno: Day 36
|
Change in respiratory rate measured in breaths per minute
|
Day 36
|
Change in body temperature
Časové okno: Day 36
|
Change in body temperature measured in degrees Celsius
|
Day 36
|
Change in ECG results
Časové okno: Day 1
|
Change in ECG results.
Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant
|
Day 1
|
Change in ECG results
Časové okno: Day 8
|
Change in ECG results.
Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant
|
Day 8
|
Change in ECG results
Časové okno: Day 15
|
Change in ECG results.
Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant
|
Day 15
|
Change in ECG results
Časové okno: Day 22
|
Change in ECG results.
Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant
|
Day 22
|
Change in ECG results
Časové okno: Day 29
|
Change in ECG results.
Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant
|
Day 29
|
Change in ECG results
Časové okno: Day 36
|
Change in ECG results.
Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant
|
Day 36
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Maximum effect for the item "energetic" on the DEQ
Časové okno: Day 1
|
Maximum effect for the item "energetic" on the Drug Effects Questionnaire.
Scale from 0-100 where higher scores indicate more "energetic"
|
Day 1
|
Maximum effect for the item "energetic" on the DEQ
Časové okno: Day 8
|
Maximum effect for the item "energetic" on the Drug Effects Questionnaire.
Scale from 0-100 where higher scores indicate more "energetic"
|
Day 8
|
Maximum effect for the item "energetic" on the DEQ
Časové okno: Day 15
|
Maximum effect for the item "energetic" on the Drug Effects Questionnaire.
Scale from 0-100 where higher scores indicate more "energetic"
|
Day 15
|
Maximum effect for the item "energetic" on the DEQ
Časové okno: Day 22
|
Maximum effect for the item "energetic" on the Drug Effects Questionnaire.
Scale from 0-100 where higher scores indicate more "energetic"
|
Day 22
|
Maximum effect for the item "energetic" on the DEQ
Časové okno: Day 29
|
Maximum effect for the item "energetic" on the Drug Effects Questionnaire.
Scale from 0-100 where higher scores indicate more "energetic"
|
Day 29
|
Maximum effect for the item "energetic" on the DEQ
Časové okno: Day 36
|
Maximum effect for the item "energetic" on the Drug Effects Questionnaire.
Scale from 0-100 where higher scores indicate more "energetic"
|
Day 36
|
Sustained attention - maximum total time on the DVT
Časové okno: Day 1
|
Sustained attention - maximum total time on the DVT
|
Day 1
|
Sustained attention - maximum total time on the DVT
Časové okno: Day 8
|
Sustained attention - maximum total time on the DVT
|
Day 8
|
Sustained attention - maximum total time on the DVT
Časové okno: Day 15
|
Sustained attention - maximum total time on the DVT
|
Day 15
|
Sustained attention - maximum total time on the DVT
Časové okno: Day 22
|
Sustained attention - maximum total time on the DVT
|
Day 22
|
Sustained attention - maximum total time on the DVT
Časové okno: Day 29
|
Sustained attention - maximum total time on the DVT
|
Day 29
|
Sustained attention - maximum total time on the DVT
Časové okno: Day 36
|
Sustained attention - maximum total time on the DVT
|
Day 36
|
Pharmacokinetic profile of THCv
Časové okno: Day 1
|
Pharmacokinetic profile of THCv measured by maximum observed plasma concentration
|
Day 1
|
Pharmacokinetic profile of THCv
Časové okno: Day 8
|
Pharmacokinetic profile of THCv measured by maximum observed plasma concentration
|
Day 8
|
Pharmacokinetic profile of THCv
Časové okno: Day 15
|
Pharmacokinetic profile of THCv measured by maximum observed plasma concentration
|
Day 15
|
Pharmacokinetic profile of THCv
Časové okno: Day 22
|
Pharmacokinetic profile of THCv measured by maximum observed plasma concentration
|
Day 22
|
Pharmacokinetic profile of THCv
Časové okno: Day 29
|
Pharmacokinetic profile of THCv measured by maximum observed plasma concentration
|
Day 29
|
Pharmacokinetic profile of THCv
Časové okno: Day 36
|
Pharmacokinetic profile of THCv measured by maximum observed plasma concentration
|
Day 36
|
Pharmacokinetic profile of THCv
Časové okno: Day 1
|
Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration
|
Day 1
|
Pharmacokinetic profile of THCv
Časové okno: Day 8
|
Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration
|
Day 8
|
Pharmacokinetic profile of THCv
Časové okno: Day 15
|
Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration
|
Day 15
|
Pharmacokinetic profile of THCv
Časové okno: Day 22
|
Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration
|
Day 22
|
Pharmacokinetic profile of THCv
Časové okno: Day 29
|
Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration
|
Day 29
|
Pharmacokinetic profile of THCv
Časové okno: Day 36
|
Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration
|
Day 36
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia (Aktuální)
11. ledna 2022
Primární dokončení (Aktuální)
6. května 2022
Dokončení studie (Aktuální)
6. května 2022
Termíny zápisu do studia
První předloženo
31. prosince 2021
První předloženo, které splnilo kritéria kontroly kvality
14. ledna 2022
První zveřejněno (Aktuální)
27. ledna 2022
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
13. května 2022
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
11. května 2022
Naposledy ověřeno
1. května 2022
Více informací
Termíny související s touto studií
Další identifikační čísla studie
- 710022US1312
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Ne
Studuje produkt zařízení regulovaný americkým úřadem FDA
Ne
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Zdraví dospělí
-
University of ZurichDokončenoOutcome Assessment, Health CareŠvýcarsko
-
University of BernUniversity Hospital Inselspital, BerneDokončenoNeuroscience of Dreaming, HealthŠvýcarsko
-
University of Colorado, DenverEunice Kennedy Shriver National Institute of Child Health and Human Development... a další spolupracovníciAktivní, ne náborPreventivní zdravotní služby (PREV HEALTH SERV)Spojené státy
-
Queens College, The City University of New YorkNáborZveřejnění článků předložených American Journal of Public HealthSpojené státy
-
Kliniek ViaSanaSt. Anna Ziekenhuis, Geldrop, NetherlandsDokončenoBolest | Užívání opioidů | Totální náhrada kolena | Aplikace E-healthHolandsko
-
Istanbul University - Cerrahpasa (IUC)NáborKardiochirurgie, Srdeční chirurgie, Výuka propouštění, Ošetřovatelství, Telenutriční péče, m-Health, Kvalita života, ZotaveníKrocan
-
FIDMAG Germanes HospitalàriesUniversity of BarcelonaZatím nenabírámePorucha duševního zdraví | Duševní zdraví wellness 1 | Role sestry | Care Acceptor, Health | Vztah, sestra pacienta
-
University of AarhusRegion MidtJylland Denmark; Tryg Danmark; Randers Municipality, DenmarkNeznámýKardiovaskulární onemocnění | Podpora zdraví | Duševní zdraví | Fyzická nečinnost | Self-reported Quality of HealthDánsko
-
Yorkshire Ambulance Service NHS TrustUniversity of BradfordZatím nenabírámeTestování Point of Care | Klinické rozhodování | Komunitní urgentní a pohotovostní péče | Allied Health Professional
-
4Life Research, LLCDokončenoSin Health | Hydratace pleti | Kožní vrásky | Kožní porfyriny | Červené skvrny na kůži obličeje | Červená vaskulatura kůže obličejeSpojené státy
Klinické studie na THCv
-
Medical Life Care Planners, LLCDokončenoHyperglykémie | Metabolický syndrom | Hypercholesterolémie | Morbidní obezitaSpojené státy
-
Jazz PharmaceuticalsDokončenoDiabetes mellitus, typ 2 | DyslipidemieSpojené království
-
Gregory L Smith, MD, MPHNáborAndrogenetická alopecieSpojené státy